AstraZeneca (AZN) and Daiichi Sankyo's combination of Enhertu plus pertuzumab has been approved in the European Union as a first-line treatment of patients with HER2-positive metastatic breast cancer, the companies said Tuesday.

The approval triggers a $100 million milestone payment by AstraZeneca to Daiichi Sankyo. It was based on a phase 3 study that showed the drug combination reduced the risk of disease progression or death by 44% compared with the standard of care.

Astrazeneca also said it has completed its previously announced worldwide exclusive license agreement with Dizal Pharamceutical for Zegfrovy, a treatment for patients with lung cancer.

The company will make an upfront payment of $600 million to Dizal, along with additional payments of up to $900 million on achievement of specific development.

Under the deal, Dizal will also receive royalties on sales of Zegfrovy, the company said.

The payout does not impact AstraZeneca's 2026 financial guidance, it added.

AstraZeneca shares were down more than 1% in recent premarket trading.